Guancial Elizabeth A, Bellmunt Joaquim, Yeh Shuyuan, Rosenberg Jonathan E, Berman David M
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Wilmot Cancer Center, University of Rochester, Rochester, NY.
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Hospital del Mar Research Institute-IMIM, Barcelona, Spain.
Urol Oncol. 2014 Jan;32(1):41.e31-40. doi: 10.1016/j.urolonc.2013.04.014. Epub 2013 Aug 2.
Micro ribonucleic acid (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC; we provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes and critically evaluate the literature on the implications of altered miR expression in BC.
We searched the English language literature for original and review articles in PubMed from 1993 to March 2013, using the terms "microRNA" and "bladder cancer," "transitional cell carcinoma," or "urothelial carcinoma." This search yielded 133 unique articles with more than 85% of them published within the last 3 years.
To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down-regulation of miRs, including those that target the fibroblast growth factor 3 pathway, such as miR-145, miR-101, miR-100, and miR-99a, has been observed in low-grade, non-muscle invasive BC. In contrast, generalized increased expression of miRs is observed in high-grade, muscle-invasive BC compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors that promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family.
Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target-prediction models.
微小核糖核酸(miR)表达在包括膀胱癌(BC)在内的泌尿系统恶性肿瘤中会发生改变。已表明单个miR可调节多种促成BC的信号通路。我们回顾了关于miR在BC中作用的主要文献;我们对miR作为肿瘤抑制因子和癌基因的加工、调控及功能进行了概述,并严格评估了关于BC中miR表达改变的影响的文献。
我们在PubMed中检索了1993年至2013年3月期间的英文原创及综述文章,使用了“微小RNA”和“膀胱癌”“移行细胞癌”或“尿路上皮癌”等术语。该检索产生了133篇独特的文章,其中超过85%是在过去3年内发表的。
迄今为止,BC中大多数miR研究使用表达谱来描述miR表达在不同分期和分级中的动态变化。在低级别、非肌层浸润性BC中观察到miR普遍下调,包括那些靶向成纤维细胞生长因子3通路的miR,如miR - 145、miR - 101、miR - 100和miR - 99a。相比之下,与相邻正常膀胱尿路上皮相比,在高级别、肌层浸润性BC中观察到miR表达普遍增加,包括预测靶向p53的miR,如miR - 21和miR - 373。此外,p53通过调控miR200家族抑制促进间充质分化的转录因子ZEB - 1和ZEB - 2。
在非肌层浸润性BC和肌层浸润性BC之间鉴定出的miR表达异常为区分膀胱癌发生的两条平行途径中已知的分子改变提供了见解。肿瘤标本和研究方法的异质性限制了不同研究之间miR表达谱变化的可重复性,并突出了在利用计算机miR靶标预测模型的领域中进行体内验证的重要性。